THERAPIX BIOSCIENCES LTD. Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update

THERAPIX BIOSCIENCES LTD.

Therapix Biosciences Reports Second Quarter

2018 Financial Results and

Provides Business Update

AVIV, Israel, August 20, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical

company focusing on the development of cannabinoid-based treatments, issued today its financial summary - second

quarter 2018 vs. second quarter 2017 (Note: The functional currency of the Company is New Israeli Shekel; for presentation purposes,

the financial data herein is presented in USD):

Business update and developments

in the Company's clinical R&D programs:

Tourette Syndrome (TS):

Obstructive Sleep Apnea (OSA):

Mild Cognitive Impairment (MCI):

THX-150 is a pharmaceutical composition

of dronabinol (synthetic 9-tetrahydracannabinol) with or without palmitoylethanolamide (PEA) along with a selected antibacterial

agent that may possess synergy potential. Our objective is to use our entourage technology in association with THC to potentially

increase the efficacy of existing antibiotic drugs especially in antibiotic-resistant bacteria strains. In addition, we have initiated

a study in an animal model of a microbial infection to test the potential efficacy and safety of THX-150 in accordance with the

plan schedule during the second half of 2018.

STATEMENTS OF FINANCIAL POSITION

(Mainly based on an effective

exchange rate of 3.65 NIS/USD as of June 30, 2018)

STATEMENTS OF PROFIT OR LOSS

(Based on the average exchange rate of

3.56 NIS/USD for the six-month period ended June 30, 2018)

STATEMENTS OF COMPREHENSIVE INCOME

(Based on the average exchange rate of

3.56 NIS/USD for the six-month period ended June 30, 2018)

STATEMENTS OF CHANGES IN EQUITY

(Mainly based on the average exchange rate

of 3.56 NIS/USD for the six-month period ended June 30, 2018)

STATEMENTS OF CHANGES IN EQUITY

(Mainly based on the average exchange rate

of 3.56 NIS/USD for the six-month period ended June 30, 2018)

STATEMENTS OF CHANGES IN EQUITY

(Mainly based on the average exchange rate

of 3.56 NIS/USD for the six-month period ended June 30, 2018)

STATEMENTS OF CHANGES IN EQUITY

(Mainly based on the average exchange rate

of 3.56 NIS/USD for the six-month period ended June 30, 2018)

(1) Net issuance expenses of $156,000

STATEMENTS OF CHANGES IN EQUITY

(Mainly based on the average exchange rate

of 3.56 NIS/USD for the six-month period ended June 30, 2018)

STATEMENTS OF CASH FLOWS

(Based on the average exchange rate of

3.56 NIS/USD for the six-month period ended June 30, 2018)

(Based on the average exchange rate of

3.56 NIS/USD for the six-month period ended June 30, 2018)

On July 31, 2018, the Company entered into

an Agreement for Convertible Equity (the "Convertible Equity Agreement") with Therapix Healthcare Resources, Inc. ("THR"),

which is a company incorporated in Delaware and an unaffiliated third party. Under the Convertible Equity Agreement, the Company

loaned an aggregate of $1,300,000 (the "Loan") to THR. The maturity date of the Loan, which accrues interest at a rate

of nine percent (9%) per annum, will be upon demand of the Company at any time after August 1, 2018, the closing date (the "Maturity

Date"). At the election of the Company, the entire Loan shall be converted into that number of shares of the most senior

class of shares of THR existing at the time of such conversion, at a price per share equal to the fair market value of such shares

as shall be determined by THR's Board of Directors, it being acknowledged that, following the exercise of such conversion

right, the Company shall hold 20.96% of THR. In addition, the Company shall have the right to appoint 50% of the members of the

THR Board of Directors. The proceeds of the Loan were used by THR to acquire eight pain clinics, seven of which are located in

Tennessee and one in Arkansas, as well as a fully equipped laboratory in Tennessee from Anesthesia Services Associates PLLC. (d/b/a

Comprehensive Pain Specialist) on August 1, 2018.

About Therapix Biosciences Ltd.:

Therapix Biosciences Ltd. is a specialty

clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and

enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently

engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the

treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of pain; THX-130 for

the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases;

and THX-160 for the treatment of pain. Please visit our website for more information at www.therapixbio.com.

About TXH-110 (Previously referred to

as THX-TS01 and THX-OSA01):

THX-110 is a combination drug candidate

for the treatment of Tourette syndrome, Obstructive Sleep Apnea and pain. It is composed of two components: (1) dronabinol (an

FDA approved analog of 9-tetrahydracannabinol, or "THC"), and (2) palmitoylethanolamide ("PEA"), which

is an endogenous fatty acid amide that belongs to the class of nuclear factor agonists, which are molecules that regulate the expression

of genes. The combination of THC and PEA may induce a reaction known as the "Entourage Effect". The basic tenet of the

entourage effect is that cannabinoids work together, or possess synergy, and affect the body in a mechanism similar to the body's

own endocannabinoid system, which is a group of molecules and receptors in the brain that mediates the psychoactive effects of

cannabis. This entourage effect may account for the pharmacological actions of PEA. Based on an activity enhancement of other physiological

compounds, PEA may indirectly stimulate the cannabinoid receptors by potentiating their affinity for a receptor or by inhibiting

their metabolic degradation, and by doing so, may increase the uptake of cannabinoid compounds, such as THC. Thus, it is speculated

that the presence of the PEA molecule could increase the efficacy of THC, while reducing the required dosage and decreasing associated

deleterious adverse events.

THX-130 is a proprietary, innovative, formulation

of ultra-low dose dronabinol, which is intended to provide a treatment for Mild Cognitive Impairment (MCI). Recent pre-clinical

animal studies have found that an ultra-low dose of THC could potentially protect the brain from long-term cognitive impairment,

which may be caused by aging, lack of oxygen supply, seizures or use of drugs. Certain pre-clinical studies also suggest that ultra-low

doses of THC cause animals to improve performance in behavioral tests that measure learning and memory.